While pharmacological intervention at this site would be instrumental to prevent atherosclerosis progression, current estrogenic agents lack ER subtype-, cell type- and, at least in part, tissue selectivity, leading to systemic undesired effects. Here, ESR1 is linked to atherosclerosis.